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related disorders that can lead to novel treatments of these 
disorders. Specifically, finding ways to limit the effects of 
apoptosis on αS aggregation, deposition, local uptake and 
subsequent propagation might significantly impact pro-
gression of disease.
Keywords Aggregation · Apoptosis · 6OHDA · Lamin 
B1 · MPP+ · Nuclear membrane integrity · Parkinson’s 
disease · Proaggregant nuclear factors · α-Synuclein
Introduction
Neuronal intracellular aggregates of α-synuclein (αS) in 
Lewy bodies and Lewy neurites are pathological features 
of Parkinson’s disease (PD) and related synucleinopathies 
such as dementia with Lewy bodies [1]. Although the 
mechanisms underlying αS pathology remain unclear, the 
possibility that abnormal conformers of αS may propagate 
from one cell to another has drawn increasing attention [2, 
3]. Cell-to-cell propagation has been proposed to explain 
the spread of αS pathology observed in cross-sectional 
studies of brains with a range of severity of PD pathology 
and conceptually organized into stages by Braak et al. [4]. 
The presence of αS pathology in neurons of embryonic 
mesencephalic grafts implanted into the neostriatum to 
treat PD patients after a lag of about 10 years also supports 
the possibility that αS spreads from host to graft [5, 6]. In 
addition, a growing body of in vivo and in vitro experi-
mental evidence supports the possibility that αS can spread 
from cell to cell [7–11]. Inherent to this hypothesis is initial 
formation of “seeds” of abnormal αS in selectively vulner-
able neuronal populations, which subsequently propagate 
[3, 12]. The origin of the seeds in experimental studies has 
been abnormal conformers of recombinant wild-type or 
Abstract Cell-to-cell transmission of α-synuclein (αS) 
aggregates has been proposed to be responsible for pro-
gressive αS pathology in Parkinson disease (PD) and 
related disorders, including dementia with Lewy bodies. 
In support of this concept, a growing body of in vitro and 
in vivo experimental evidence shows that exogenously 
introduced αS aggregates can spread into surround-
ing cells and trigger PD-like pathology. It remains to be 
determined what factor(s) lead to initiation of αS aggre-
gation that is capable of seeding subsequent propagation. 
In this study we demonstrate that filamentous αS aggre-
gates form in neurons in response to apoptosis induced 
by staurosporine or other toxins-6-hydroxy-dopamine 
and 1-methyl-4-phenylpyridinium (MPP+). Interac-
tion between αS and proaggregant nuclear factor(s) is 
associated with disruption of nuclear envelope integrity. 
Knocking down a key nuclear envelop constituent protein, 
lamin B1, enhances αS aggregation. Moreover, in vitro 
and in vivo experimental models demonstrate that aggre-
gates released upon cell breakdown can be taken up by 
surrounding cells. Accordingly, we suggest that at least 
some αS aggregation might be related to neuronal apopto-
sis or loss of nuclear membrane integrity, exposing cyto-
solic α-synuclein to proaggregant nuclear factors. These 
findings provide new clues to the pathogenesis of PD and 
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mutant αS or sonicated fractions “preformed fibrils” from 
post-mortem PD brains [8–10].
Neurodegeneration in PD and related disorders is a 
chronic, progressive process associated with neuronal cell 
death, associated energy failure and disruption of cellular 
integrity, which are features of cells undergoing apoptosis 
[13]. Evidence from postmortem brains of PD [14, 15], ani-
mal models of PD [16, 17], as well as in vitro cell culture 
studies [18, 19] strongly suggest that αS-associated neu-
ronal death is apoptotic. Moreover, there is evidence for 
a proapoptotic environment in the substantia nigra in PD 
[14]. The identification of high-molecular-weight αS spe-
cies in cells expressing αS subjected to apoptosis [20, 21] 
prompted us to investigate if αS aggregation is induced by 
apoptosis and to determine factor(s) that promote patho-
logic αS aggregation, which may be seeds for eventual cell-
to-cell transmission.
In the present study, we employed cell- and animal-
based studies to explore mechanisms of αS aggregation 
in apoptotic neurons. We demonstrate that filamentous αS 
aggregates rapidly form in apoptotic neurons through an 
interaction between αS and proaggregant nuclear factor(s) 
following disruption of the nuclear envelope. Moreover, αS 
aggregates released upon cell breakdown can be taken up 
by surrounding cells in both in vitro and in vivo experimen-
tal models. These data support the possibility that loss of 
nuclear membrane integrity plays an important role in αS 
pathology.
Materials and methods
Cell culture and maintenance
We used a dopaminergic neuronal cell model, BE(2)-
M17D/3D5, which is derived from human neuroblastoma 
BE(2)-M17D cell line [22] that expresses human wild-
type αS upon TetOff induction and displays neuronal phe-
notypes under retinoic acid-induced differentiation [23]. 
BE(2)-M17D/3D5 cells were maintained in DMEM/10 % 
fetal bovine serum with 2 μg⁄ml Tet at 37 °C and 5 % 
CO2. Cells were seeded at the density of 3 × 106 cells/
plate (100 × 20 mm, BD Biosciences, San Jose, CA) 
or 5.0 × 105 cells/well in 6-well plates for biochemical 
analysis, and 2 × 104 cells/well on coverslips in 24-well 
plates for immunocytochemistry. For differentiation and αS 
induction, media were replaced with Neurobasal medium 
(Invitrogen, Thermo Fisher, Waltham, MA), 2 % B-27 
supplement (Invitrogen, Thermo Fisher), 2 mM l-glu-
tamine (Sigma-Aldrich, Saint Louis, MO) and 10 μM RA 
(Sigma-Aldrich).
A previously described H4 neuroglioma cell line that 
inducibly co-expresses the N-terminal half of Venus 
YFP tagged to αS (V1S) and C-terminal half of Venus 
YFP tagged αS (SV2) upon TetOff induction, named 
as H4/V1S-SV2 [24], were maintained in OPTI-MEM 
(Invitrogen) medium supplemented with 10 % fetal 
bovine serum (Invitrogen), 200 µg/ml Hygromycin 
B, 200 µg/ml G418 and 2 μg⁄ml Tet and incubated at 
37 °C.
The Lund human mesencephalic (LUHMES) cell line 
(LUHMES ATCC® CR-2927) is a subclone of the Tet-
controlled, v-myc-overexpressing human mesencephalic-
derived cell line. It can be differentiated into dopamine-
like neurons [25]. Cells were cultured in advanced 
DMEM/F-12/Glutamax medium supplemented with 
N2 supplement (Invitrogen) and 40 ng/ml FGF2 (R&D 
Systems, Minneapolis, MN) at 37 °C according to pub-
lished methods [26]. Culture plates were pre-coated with 
50 µg/ml poly-l-ornithine (Sigma-Aldrich) and 1 µg/ml 
fibronectin (Sigma-Aldrich, F1141). For differentiation, 
media were replaced with advanced DMEM/F-12/Glu-
tamax/N2 medium (Invitrogen) containing 2 ng/ml human 
recombinant glial cell-derived neurotrophic factor (R&D 
Systems), 1 mM cAMP (Sigma-Aldrich) and 1 µg/ml Tet 
for 4 days.
For primary cultures, cortical/hippocampal neurons 
from embryonic C57BL/6 wild-type mice were seeded on 
poly-d-lysine (Sigma-Aldrich) coated 6-well plate at about 
1 × 106 cells per well. Experimental protocols for primary 
cultures were the same as those reported previously [27].
Lentiviral plasmids and virus preparation
Lentiviral plasmids carrying αS (EX-G0543-Lv105) were 
purchased from Genecopoeia, Rockville, MD, and shRNAs 
of human LMNB1 were purchased from Sigma-Aldrich. 
The preparation of Lentivirus carrying genes of interest or 
shRNA was the same as described previously [28].
Isolation of nuclear and cytoplasmic fractions
Nuclear and cytoplasmic fractions were isolated using NE-
PER nuclear and cytoplasmic extraction reagents (Thermo 
Scientific, Waltham, MA) following the manufacturer’s 
instructions, but with some modifications. Briefly, cells 
were resuspended in cytoplasmic extraction reagent I, incu-
bated for 10 min, followed by the addition of cytoplasmic 
extraction reagent II and centrifugation at 16000×g for 
5 min. Supernatant was kept as cytoplasmic fraction. The 
insoluble pellet was further mixed with nuclear extraction 
reagent and subjected to sonication for 3 min followed by 
centrifugation at 16000×g for 10 min. The supernatant was 
then kept as nuclear fraction. The whole process was done 
on ice or at 4 °C. The bicinchoninic acid (BCA) assay was 
used for protein quantitation.
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Isolation of apoptotic bodies
Apoptotic bodies were isolated according to a previ-
ously reported protocol [29]. Medium from 10 plates 
(100 × 20 mm) of apoptotic neurons was collected and 
clarified from dead cells and cell debris by centrifugation 
(800×g, 10 min). The apoptotic body-enriched superna-
tant was further centrifuged (16000×g, 20 min) to gener-
ate a final pellet containing apoptotic bodies. The pellet 
was either stored at −80 °C for future use or resuspended 
immediately in PBS.
Fractionation studies of apoptotic bodies and electron 
microscopy
Apoptotic bodies were fractionated to derive 1 % sarkosyl-
insoluble material following previously reported protocols 
[27]. The sarkosyl-insoluble material was resuspended in 
50 mM Tris (pH 8.0) and used for electron microscopy and 
immunoelectron microscopy as described previously [30].
Sample preparation and western blot analysis
Cell cultures were harvested and centrifuged at 200×g 
for 15 min. The pellets were resuspended in MES buffer 
(20 mM MES, pH 6.8; 80 mM NaCl, 1 mM MgCl2, 2 mM 
EGTA, 10 mM NaH2PO4, 20 mM NaF, phenylmethylsul-
fonyl fluoride PMSF, 1 μg/ml and leupeptin, 10 μg/mL) 
[22] supplemented with phosphatase inhibitors and then 
sonicated for 1 min, followed by centrifugation at 180×g 
for 15 min. The whole process was done at 4 °C. The cell 
lysates were mixed with 6 × SDS-PAGE sample buffer 
(375 mM Tris–HCl, 12 % SDS, 60 % Glycerol, 12 % 2–
Mercaptoethanol, 0.03 % Bromophenol blue), boiled for 
10 min and resolved by SDS-PAGE using 10–20 % Tris/
Glycine gel (Bio-Rad, Hercules, California). Precision 
Plus protein standards (Bio-Rad) were included as refer-
ences. After gel electrophoresis, proteins were transferred 
onto polyvinylidene difluoride (PVDF) membranes. Anti-
bodies used for western blot studies are as follows: total 
αS (Syn1; mouse monoclonal IgG1; cat. #: 610787) from 
BD Bioscience; phospho-serine-129 αS (pSyn #64, mouse 
IgG1; cat #: 015-25191) from Wako USA, Richmond, VA; 
pore membrane protein of 121 kDa (POM121) (N2N3, rab-
bit polyclonal; cat #: GTX102128) from GeneTex, Irvine, 
CA; lamin B1 (LMNB1) (rabbit polyclonal; cat #: 12987-
1-AP) from Proteintech, Rosemont, IL; Histone H3 (rabbit 
polyclonal; cat # ab1791) from Abcam, Cambridge, MA; 
cleaved caspase 3 (rabbit polyclonal to human cleaved cas-
pase 3 (Asp175); cat #: 9661) from Cell Signaling, Dan-
vers, MA; α-tubulin (rabbit monoclonal; Epitomics cat #: 
1878-1) from Abcam, Cambridge, MA; and β-actin (mouse 
monoclonal IgG2a; cat #: A5316) from Sigma, Saint Louis, 
MO (A5316). Western Lightning Plus ECL (PerkinElmer, 
Bridgeville, PA) or ECL™ Prime Western Blotting Detec-
tion Reagent (Fisher Scientific, Pittsburgh, PA) was used 
for visualization of protein immunoreactivities. The results 
of western blots were quantified using ImageJ software. 
Expression levels of proteins of interest were normalized to 
internal control. Data from at least 3 sets of independent 
experiments were analyzed by one-way ANOVA with Dun-
nett’s post hoc test for statistical significance.
Time‑lapse confocal microscopy imaging
H4/V1S-SV2 cells with αS induction for 5 days were cul-
tured in reduced serum medium (Cat. No. 31985-062, Inv-
itrogen) in Lab-Tek™ Chambered Cover Glass System (4 
well, Nunc™ Lab-Tek II, Sigma-Aldrich). After exposure 
to staurosporine (STS), cells were subjected to time lapse 
imaging (interval time = 10 min, 16 h for early or 36 h for 
later stage of apoptosis) by confocal microscopy (Zeiss 
LSM 510, Carl Zeiss MicroImaging, Pleasanton, CA) at 
37 °C to monitor formation and distribution of αS aggre-
gates. Three independent experiments were performed to 
confirm the results. In each experiment, 5 fields (upper left, 
upper right, center, lower left and lower right) with at least 
90 cells were chosen for counting the ratio of cells having 
predominant αS aggregation in nuclei after 16 h of STS 
treatment.
Immunocytochemistry
Cells grown on cover slips were rinsed with PBS, fixed 
in 4 % paraformaldehyde and permeabilized with 0.1 M 
Tris-buffered saline (TBS; pH 7.6) containing 0.5 % Tri-
ton X-100 for 5 min. They were subsequently blocked with 
3 % goat serum in TBS, incubated with primary antibod-
ies (rabbit anti-Flag from Sigma Aldrich, mouse anti-Myc 
from cell signaling, or LB509 from Invitrogen) in TBS 
containing 1 % goat serum overnight at 4 °C and then incu-
bated for 1 h with secondary antibodies. Immunolabeled 
cells were stained with nuclear stain DAPI (Invitrogen) for 
10 min and observed by confocal fluorescence microscopy 
(Zeiss LSM 510, Carl Zeiss MicroImaging, Pleasanton, 
CA). Three independent experiments were performed to 
confirm the results. For each in situ cell uptake experiment, 
at least 60 αS-Flag cells were included for counting of cells 
bearing particles positive with Myc and Flag tags.
Stereotaxic surgery
All animal procedures were approved by the Mayo Clinic 
Institutional Animal Care and Use Committee. C57BL/6 mice 
(12 months of age) were anesthetized with 3 % isoflurane 
and stereotaxically injected with different samples. For cell 
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lysates and apoptotic bodies, 20 µg total protein per brain was 
injected. Control mice were injected with PBS to exclude any 
effects due to surgery and injection. A single-needle insertion 
(coordinates: X = 2.0 mm; Y = 0.2 mm; Z = 0.8 and 2.6 mm, 
respectively) into the left forebrain was used to deliver the 
inoculum to somatosensory cortex and dorsal neostriatum. 
Material was injected via a Hamilton syringe at a rate of 
0.5 μl per min (5 μl total per site). After recovery from sur-
gery, animals were monitored regularly. A week later, animals 
were subjected to transcardial perfusion with PBS, and brains 
were fixed in 10 % formalin followed by paraffin embedding. 
Coronal sections were cut at 5-micron thickness for immuno-
histochemical and immunofluorescent staining.
Thioflavin T binding
Apoptotic bodies were resuspended in TBS at pH 7.4 and 
10 µM Thioflavin T. Fluorescence was measured immedi-
ately at 440 nm (excitation)/460–600 nm (emission) with a 
Cary Eclipse fluorescence spectrophotometer (Varian, Palo 
Alto, CA). After subtraction of background signals from 
reagent alone, the fluorescent signals from the peak areas 
were integrated [31].
Immunohistochemical and immunofluorescent staining
Sections of paraffin-embedded tissue were sequentially 
subjected to deparaffinization, rehydration, steaming in 
DAKO target retrieval solution pH 6.1 for 30 min, diges-
tion with Protease 24 for 8 min at room temperature (only 
for staining with LB509) and blocking with Protein Block 
(X0909, DAKO, Carpinteria, CA) for 1 h at room tempera-
ture. For immunoperoxidase labeling, sections were treated 
with 3 % hydrogen peroxide to block endogenous peroxi-
dase and then incubated with 5 % normal goat serum for 
20 min to reduce non-specific labeling. Tissue sections 
were incubated with antibodies to αS (LB509, 1:100, Invit-
rogen) for 45 min and Envision-Plus labeled polymer HRP, 
rabbit or mouse (DAKO) for 30 min. Peroxidase labeling 
was visualized with a solution containing 3, 3′-diamin-
obenzidine (DAB-Plus). The sections were subsequently 
counterstained with Lerner 1 hematoxylin (14-930-11, 
Fisher Scientific) and coverslipped with cytoseal mounting 
medium (8310-16, Richard-Allan Scientific, Kalamazoo, 
MI). For immunofluorescence, sections were incubated 
with Protein Block (X0909, DAKO) for 1 h at room tem-
perature. The sections were incubated with antibodies to 
MAP2 (1:1000, chicken polyclonal, EnCor Biotechnology, 
Gainesville, FL) and αS (LB509, 1:100, Invitrogen) at 4 °C 
overnight, followed by 1.5 h of incubation with second-
ary antibodies (1:500) after washing. Non-specific fluores-
cence signals were blocked by staining with Sudan Black. 
Sections were coverslipped with Vectashield mounting 
media (H-1200, Vector Laboratories, Burlingame, CA) and 
viewed with confocal microscopy.
Results
Induction of insoluble αS in cellular models 
by apoptosis
To determine if apoptosis can trigger intracellular αS 
aggregation, staurosporine (STS), a well-known neuronal 
apoptosis inducer, was used to treat differentiated BE(2)-
M17D/3D5 cells because it has been shown that exposure 
of neurons to 30–100 nM STS can induce concentration-
dependent apoptotic degeneration [32]. As expected, 
BE(2)-M17D/3D5 cells exposed to 50 or 100 nM STS 
showed time- and dose-dependent increases in both cleaved 
caspase 3, a molecular marker of apoptosis, and in SDS-
resistant aggregated αS (Fig. 1). αS aggregation was 
observed as early as 4 h after exposure to STS (Fig. 1c, 
e), indicating that factor(s) associated with apoptosis rap-
idly trigger pathologic assembly of αS. Pretreatment with a 
caspase inhibitor (CI)-Z-VAD-FMK, a cell-permeant pan-
caspase inhibitor that irreversibly binds to the catalytic site 
of caspase proteases, significantly reduced both caspase 
activation and αS aggregation (Fig. 1c, e), confirming that 
apoptosis contributes to formation of αS aggregates.
To determine whether αS aggregation in response to 
apoptosis is unique to BE(2)-M17D/3D5 cells, we included 
two other cell models, differentiated LUHMES cells 
(Fig. 2a) and primary mouse cortical neurons (Fig. 2b). 
Since increased levels of αS can accelerate aggrega-
tion [33], the two cell models were infected with lentivi-
rus carrying human αS to increase its expression. In both 
cell models SDS-resistant αS aggregates formed after STS 
treatment in a time-dependent manner, and pretreatment 
with the caspase inhibitor blocked both apoptosis and αS 
aggregation (Fig. 2).
To further determine if apoptosis-triggered αS aggrega-
tion has physiological relevance, we used STS to treat pri-
mary neurons bearing only endogenous αS. As a positive 
control, we included sibling cultures infected with lenti-
virus carrying human αS. The results showed that endog-
enous αS (EN) can also form aggregates in response to STS 
treatment, but the magnitude of aggregation is much less 
compared to that in neurons overexpressing αS (EX) with 
lentivirus infection (Fig. 2c).
Fluorescent complementation shows αS aggregates 
in nuclei during induction of apoptosis
To study dynamic changes in αS aggregation during apop-
tosis, a fluorescence complementation assay with the H4/
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V1S-SV2 cell line was used. This cell line expresses αS 
tagged with a split Venus YFP molecule. Binding of V1S to 
SV2 upon αS–αS interaction can reconstitute fluorescence 
and indicates αS aggregation [24]. After 5 days of induc-
tion, H4/V1S-SV2 cells were exposed to 25 nM STS and 
subjected to time-lapse confocal microscopy to monitor αS 
aggregation. Unexpectedly, after 16 h of STS treatment, 
most cells (91 ± 3 %) showed predominant fluorescent 
signals in nuclei, suggesting that the nuclear environment 
in neurons undergoing apoptosis favors αS aggregation. 
At later stages of apoptosis, associated with nuclear con-
densation, αS aggregates were detected in the cytoplasm, 
and finally they were released into the media, where some 
bound to nearby cells (Fig. 3a, b).
Apoptosis‑induced αS aggregates are found in nuclear 
and cytoplasmic fractions
To support findings from live cell imaging, we per-
formed nuclear and cytoplasmic protein fractionation of 
STS-treated neuronal cultures. The BE(2)-M17D/3D5 
human dopaminergic cell line was chosen because it 
inducibly expresses wild-type human αS at a high level 
amenable to biochemical analyses [23]. Differentiated 
BE(2)-M17D/3D5 cells with 5 days of αS induction were 
collected at various time points following exposure to STS. 
Nuclear and cytoplasmic fractions were prepared and ana-
lyzed with dot blots, as well as with sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) western 
blots. As expected, dot blots revealed more αS in cytoplas-
mic than nuclear fractions (Fig. 3c, Supplementary Fig. 
A1), consistent with previous study results showing that αS 
is predominantly a cytoplasmic protein. Total αS progres-
sively increased in the nuclear fraction following induction 
of apoptosis with STS, suggesting that αS translocates to 
the nucleus with apoptosis. Western blots showed that the 
cytoplasmic fraction had much more monomeric αS than 
the nuclear fraction when the same amount of total proteins 
from each fraction were compared; whereas higher molecu-
lar weight αS aggregates are more apparent in nuclear com-
pared to cytoplasmic fractions (Fig. 3c, Supplementary Fig. 
A1). These results suggest that the nuclear fraction contains 
factor(s) that promote αS assembly. Moreover, αS aggrega-
tion increases in a time-dependent manner after induction 
Fig. 1  Apoptosis induces αS aggregation and phosphorylation in 
BE(2)-M17D/3D5 cells. a The basic paradigm for cell differentiation, 
αS induction and staurosporine (STS) treatment. BE(2)-M17D/3D5 
cells with 5 days of differentiation and αS induction were exposed to 
25 nM STS for 0, 8, 16 and 24 h before harvest. b STS treatment 
of BE(2)-M17D/3D5 cells induces apoptosis, αS aggregation and 
Serine 129 phosphorylation, and degradation of lamin B1 (LMNB1) 
and nuclear pore membrane protein 121 KDa (POM121) in a time-
dependent manner. c High dose of STS treatment can rapidly trigger 
apoptosis and other aforementioned effects which can be significantly 
prevented by caspase inhibitor. BE(2)-M17D/3D5 cells with 5 days 
of differentiation and αS induction were exposed to 50 and 100 nM 
for 4 h before harvest. A group of 100 nM STS-treated sibling cul-
tures was pretreated with caspase inhibitor (CI). All cell lysates were 
subjected to SDS-PAGE followed by western blotting with antibod-
ies to interesting proteins. Dot blotting of cell lysates was used to 
detect total αS level (T-αS) for quantification of p-αS/T-αS immuno-
reactivities. Molecular weight standards were included as references. 
Arrow denotes a specific cleaved caspase 3 band in BE(2)-M17D/3D5 
cells pretreated with caspase inhibitor. Number sign (#) denotes a 
non-specific Syn1-immunoreactive band on western blots of lysates 
from BE(2)-M17D/3D5 cells. d, e Statistical analysis of immunore-
activity of various proteins shown in (b and c). Bar graphs in d and 
e summarize the results of quantitative analyses of immunoreactivi-
ties of various proteins in cell lysates from three independent experi-
ments represented by b and c with normalization against β-actin or 
T-αS immunoreactivities. The average values of control group (Con 
or 0 nM) were set as 100 %. Error bars represent standard error of 
the mean (*p < 0.05, **p < 0.01, comparing to control; #p < 0.05, 
##p < 0.01, comparing subsets linked by line, n = 3)
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of apoptosis in both nuclear and cytoplasmic fractions 
(Fig. 3c, Supplementary Fig. A1). Since translocation of 
αS to the nucleus persisted during apoptosis, it was not 
surprising to see progressive increase of αS aggregation in 
the nuclear fraction with progression of apoptosis. It was 
not immediately clear why aggregation of cytoplasmic αS 
also increases with progression of apoptosis; however, it is 
possible that nuclear factor(s) promoting aggregation may 
translocate from nucleus into the cytoplasm given that a 
representative nuclear protein (histone H3, Fig. 3c) gradu-
ally increases in cytoplasmic fractions with progression of 
apoptosis (Supplementary Fig. A1).
Nuclear factor(s) that promote αS assembly shift 
to cytoplasm with apoptosis
To confirm the role of nuclear factor(s) in facilitating αS 
aggregation, the same amount of protein (50 µg) from 
nuclear and cytoplasmic fractions of differentiated null 
M17D cells (without αS overexpression) with or without 8 
and 16 h of STS treatment was incubated with freshly pre-
pared recombinant αS (10 µg) as described previously [30] 
for 30 min at 37 °C. At baseline, αS aggregates were min-
imal-to-nonexistent when recombinant αS was mixed with 
either cytoplasmic fraction buffer or nuclear fraction buffer, 
but αS aggregates rapidly appeared in preparations exposed 
to nuclear fractions from both STS-treated and non-treated 
cells (Fig. 3e, Supplementary Fig. A1), supporting the pres-
ence of nuclear factor(s) that facilitate αS aggregation. 
Interestingly, in STS-treated cells, the effect of cytoplasmic 
fraction on αS aggregation was positively correlated with 
the duration of treatment, consistent with the hypothesis 
that as apoptosis progresses, proaggregant nuclear factor(s) 
increasingly gain access to cytoplasm.
Disruption of nuclear envelope integrity 
during apoptosis and αS aggregation
Given that nuclear envelopes block free passage of mol-
ecules between nucleus and cytoplasm and that apopto-
sis is associated with degradation of the nuclear enve-
lope [34], we hypothesized that progressive increases in 
nuclear proaggregant factor(s) in the cytoplasm would 
correlate with disruption of the nuclear envelope. We 
addressed this by measuring the status of two key pro-
teins of the nuclear envelope, pore membrane protein of 
121 kDa (POM121) and lamin B1 (LMNB1), in STS-
treated neuronal cultures for their relation to increases in 
αS aggregation (Fig. 1b, c).
We postulated that neurons with compromised nuclear 
envelope integrity due to decreased expression of key 
structural components of nuclear membrane would have 
increased susceptibility to STS and that αS aggregation 
would be increased in such cells. To test whether com-
promised nuclear envelope can trigger αS aggregation, 
neurons were subjected to knockdown of LMNB1 using 
lentivirus delivered shRNA, followed by STS or vehicle 
treatment. We found neurons deficient in LMNB1 (express-
ing less than 20 % of control levels) had significantly more 
αS aggregates than cultures exposed to the same dose of 
lentivirus carrying control vector (Fig. 3g, Supplementary 
Fig. A1), suggesting that loss of nuclear envelope integrity 
was associated with increased vulnerability to αS aggrega-
tion. Cultures with LMNB1 knockdown to around 50 % of 
control had similar expression of αS as controls, but they 
had significantly more αS aggregates than controls at the 
same dose and duration of STS treatment, suggesting that 
neurons with deficient constituent proteins of nuclear enve-
lope are more vulnerable to αS aggregation.
Phospho‑serine 129 in αS aggregates of apoptotic 
neurons
Because phosphorylated αS (p-αS) accumulates in Lewy 
bodies and Lewy-related pathology [35], we immu-
nostained apoptosis-induced αS aggregates for the pres-
ence of this post-translational modification. Western blots 
of cell lysates from differentiated BE(2)-M17D/3D5 cells, 
as well as LUHMES cells and primary neurons subjected to 
Fig. 2  Apoptosis induces αS aggregation and phosphorylation in dif-
ferentiated LUHMES and primary neurons. a STS treatment induces 
apoptosis, αS aggregation and phosphorylation in a time-dependent 
manner in differentiated LUHMES cells and primary neurons. Differ-
entiated LUHMES cells and primary neuronal cultures overexpress-
ing αS via infection with lentivirus carrying αS were, respectively, 
exposed to 100 nM STS for 0, 8, 16 and 24 h before being harvested. 
b Caspase inhibitor (CI) prevents STS-induced apoptosis and αS 
aggregation in differentiated LUHMES cells and primary neuronal 
cultures. Cultures without STS treatment were used as control (Con). 
STS-treated sibling cultures were pretreated with caspase inhibi-
tor (STS/CI) to inhibit apoptosis. c Apoptosis induces aggregation 
of endogenous αS in mouse primary cultures. Primary neuronal cul-
tures with only endogenously expressed αS (EN) or with exogenously 
overexpression of αS (EX) via infection with lentivirus carrying αS 
were exposed to 100 nM STS or vehicle (Con) for 16 h before har-
vest. All cell lysates were subjected to SDS-PAGE followed by west-
ern blotting with antibodies to proteins of interesting. Dot blotting of 
cell lysates was used to detect the total αS level (T-αS) for quantifi-
cation of p-αS/T-αS immunoreactivities. Molecular weight standards 
were included as references. Number sign (#) denotes a non-specific 
Syn1-immunoreactive band on western blots of lysates from primary 
cultures. d–g Statistical analyses of immunoreactivities of various 
proteins shown in a and b. Bar graphs in d–g summarize results of 
quantitative analyses of immunoreactivities of various proteins in 
cell lysates from three independent experiments represented by a 
left, a right, b left and b right with normalization against β-actin or 
T-αS immunoreactivities. The average values of control group (Con) 
were set as 100 %. Error bars represent standard error of the mean 
(*p < 0.05, **p < 0.01, comparing to control; #p < 0.05, ##p < 0.01, 
comparing subsets linked by line, n = 3)
◂
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Fig. 3  Disruption of nuclear envelope plays an essential role in the 
rapid αS aggregation during neuronal apoptosis. a, b αS aggregation 
in response to apoptosis induction predominantly occurred in nuclei 
rather than cytoplasm in live H4/V1S-SV2 cells. H4/V1S-SV2 cells 
cultured in Nunc™ Lab-Tek chambered cover glass system were 
induced to express H4/V1S-SV2 for 4 days, then maintained in media 
containing STS and Hoechst 33342 and subjected to time-lapse imag-
ing using confocal fluorescence microscopy. A low magnification of 
live cell imaging demonstrates that about 94 % cells (30–32) had oli-
gomeric αS (Olig. αS) predominantly in nuclei of cells (see red aster-
isk * in a) under 16 h of STS treatment. High magnification of live 
imaging of a single cell showed that the majority of αS aggregates 
appears first in nuclei (arrow head in b at 18 h) and then distributed 
to cytoplasm before finally being released to surrounding cells due to 
cell breakdown (arrows in b at 36 h). Scar bar: 10 µm. c, d Frac-
tionation of cytoplasmic and nuclear proteins revealed the dynamic 
distribution of αS aggregates and other proteins in apoptotic neurons. 
Differentiated BE(2)-M17D/3D5 cells with 5 days of αS induction 
were, respectively, exposed to 25 nM for 0, 8, 16 and 24 h before har-
vest. c Nuclear and cytoplasm fractions were isolated and subjected 
to SDS-PAGE followed by western blotting. Dot blots were used to 
detect total αS (T-αS) for evaluation of the dynamic changes of T-αS 
in different fractions. α-Tubulin and histone H3 were probed to con-
firm there was no contamination between cytoplasmic and nuclear 
fraction in non-treated control group. d Ponceau S staining was per-
formed before immunostaining to demonstrate total protein in each 
group. e, f Proaggregant nuclear factor(s) diffuse into cytoplasm 
with progression of apoptosis. Nuclear and cytoplasm fractions from 
null M17D neuroblastoma cells with 0, 8 and 16 h of STS treatment 
were, respectively, isolated. Fresh recombinant αS (10 µg) was incu-
bated with the same amount of protein from each fraction for 30 min 
at 37 °C. The same amount of recombinant αS incubated with only 
cytoplasmic fraction buffer (CFB) or nuclear fraction buffer (NFB) 
was used as control. e Samples were subjected to SDS-PAGE fol-
lowed by western blotting with monoclonal antibody to αS (Syn1). 
Dot blotting was used to confirm the comparable level of input 
recombinant αS in each sample. f Ponceau S staining was performed 
to demonstrate comparable levels of protein in all samples of cyto-
plasmic and nuclear fractions. g Disintegration of nuclear envelope 
is associated with rapid αS aggregation in neuronal cells in response 
to apoptosis induction. Differentiated BE(2)-M17D/3D5 cells with 
5 days of αS induction infected with lentivirus carrying shRNA of 
LMNB1 and control vector were exposed to media with or without 
25 nM STS for 16 h. Lentivirus infection was performed on the day 
3 of culture. Left: one arbitrary unit (1x) or 3 units (3x) of lentivi-
rus were applied to cells to obtain different extent of LMNB1 knock-
down (KD). For control (Con), 3 units (3x) of lentivirus was used. 
Right: one arbitrary unit of lentivirus was used for both control (Con) 
and LMNB1 knockdown (KD). Cell lysates were subjected to SDS-
PAGE and western blotting. Number sign (#) denotes a non-specific 
Syn1-immunoreactive band on western blots of lysates from BE(2)-
M17D/3D5 cells in (c, g)
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STS-induced apoptosis all had time-dependent increases of 
p-αS (Figs. 1b, d, 2a, d, e).
Aggregation and phosphorylation of αS in neuronal 
cultures exposed to other neurotoxins
Because STS is not a toxin that triggers PD-related pathol-
ogy in humans and animal models, we performed similar 
experiments in neuronal cultures exposed to other neu-
rotoxins commonly used in PD research. Differentiated 
BE(2)-M17D/3D5 cells overexpressing αS were treated 
with 1-methyl-4-phenylpyridinium (MPP+) [36, 37] or 
6-hydroxy-dopamine (6OHDA) [38, 39]. As expected, 
time-dependent aggregation and phosphorylation of αS 
were observed in neuron cultures with apoptosis induced 
by both neurotoxins (Fig. 4a). Furthermore, nuclear and 
cytoplasmic fractionation demonstrated that (1) cyto-
plasmic fractions contained more monomeric αS than 
nuclear fractions (Fig. 4b); (2) αS aggregates that formed 
in nuclear fractions had higher molecular weight than 
those in cytoplasmic fractions; and (3) αS aggregates 
increased in a time-dependent manner upon induction of 
apoptosis in both nuclear and cytoplasmic fractions. The 
changes observed in αS aggregation and phosphorylation 
and subcellular distribution of αS aggregates in BE(2)-
M17D/3D5 cells treated with MPP+ and 6OHDA were 
similar to those observed with STS, suggesting apoptosis 
may play a role in toxicity of other neurotoxins, at least 
in terms of their effects on αS aggregation in neuronal 
cultures.
Apoptotic bodies associated with disruption of nuclear 
membrane integrity contain αS aggregates
Because αS aggregates increasingly formed during apop-
tosis and because αS aggregation at later stages of apop-
tosis was associated with unresolvable high-molecular-
weight molecular species at the top of gel (Fig. 1b, c), we 
examined the morphology of αS aggregates in cultures at 
late stages of apoptotic cell death. Thirty-six hours after 
STS treatment, differentiated BE(2)-M17D/3D5 cells were 
subjected to immunocytochemical staining with LB509 to 
detect αS aggregates [40]. At this late stage of apoptosis, 
cells showed disrupted nuclear profiles and more αS aggre-
gation than that observed in intact nuclei at earlier stages of 
apoptosis (Fig. 5a). Of note, αS aggregates were observed 
not only in apoptotic bodies, but also in smaller structures 
(arrowheads in Fig. 5a). These findings suggest that a range 
Fig. 4  Aggregation and phosphorylation of αS as well as the distri-
bution of αS aggregates in neuronal cells are induced by neurotox-
ins MPP+ and 6OHDA. Differentiated BE(2)-M17D/3D5 cells with 
5 days of αS induction were, respectively, exposed to MPP+ or 
6-6OHDA for 8, 16 and 24 h before harvest. Cells without treatment 
were used as control (Con). Each group of cells was divided into two 
parts for extraction of total cell lysates or isolation of nuclear and 
cytoplasm fractions. Samples were subjected to SDS-PAGE followed 
by western blotting with antibodies to proteins of interest. Dot blots 
of cell lysates were used to detect the total αS level (T-αS). Molecu-
lar weight standards were included as references. a Analysis of total 
lysates showed that aggregation and Serine 129 phosphorylation of 
αS gradually increased with progression of apoptosis in neuronal 
cells treated with MPP+ or 6OHDA. b Fractionation of cytoplasmic 
and nuclear proteins revealed that dynamic changes in distribution of 
αS aggregates and other proteins in neuronal cells induced by MPP+ 
or 6-6OHDA treated were similar to those induced by STS. c. Pon-
ceau S staining was performed to demonstrate that cytoplasmic and 
nuclear fraction have comparable levels of total proteins
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of αS aggregates can be released into the extracellular 
milieu from apoptotic cells.
Apoptotic bodies contain filamentous αS aggregates
Given the striking degree of αS immunoreactivity in 
apoptotic bodies, we explored their ultrastructural char-
acteristics to determine if apoptosis-associated αS was 
filamentous, as in Lewy bodies. Cell lysates from differ-
entiated BE(2)-M17D/3D5 cells without STS treatment, 
and apoptotic bodies isolated from STS-treated differen-
tiated BE(2)-M17D/3D5 cells or null M17D cells, were 
fractionated. Sarkosyl-insoluble fractions were processed 
for immunoelectron microscopy. Interestingly, filamentous 
structures were detected in BE(2)-M17D/3D5 cells derived 
from apoptotic bodies (Fig. 5b, left), but not in other sam-
ples (data not shown). The filaments were immunopositive 
for αS (Fig. 5b, right), which suggests that filamentous αS 
can be formed in apoptotic bodies of cells overexpressing 
αS.
Fig. 5  Apoptotic bodies derived from neuronal cells with αS over-
expression contain αS aggregates that are taken up by surrounding 
cells. a Apoptotic bodies with disrupted nuclear envelope have αS 
aggregates. Differentiated BE(2)-M17D/3D5 cells with 5 days of αS 
expression were induced to enter late apoptotic stage by STS treat-
ment for 36 h and then subjected to immunocytochemical staining 
with LB509 antibody and nuclear counterstaining with DAPI. Cells 
with intact nuclei are outlined (white line) in bright-field (BF) micros-
copy image. Signals of aggregated αS (Agg. αS) in cells without STS 
treatment (Con) are enhanced to demonstrate the cell morphology 
since the laser setting used for imaging STS-treated cells was not vis-
ible in control cells. Arrows and arrowheads denote apoptotic bodies 
and other smaller structures. The asterisk (*) labeled the location of 
intact nuclei in both groups. b Ultrastructural evaluation of sarkosyl-
insoluble fractions prepared from apoptotic bodies. Apoptotic bodies 
were isolated from differentiated BE(2)-M17D/3D5 cells with 5 days 
of αS expression and 36 h of STS treatment and then subjected to 
fractionation to obtain Sarkosyl-insoluble fraction. (Left) Sarkosyl-
insoluble fraction adsorbed on EM grids and negatively stained with 
5 % uranyl acetate revealed filamentous assemblies of diameter about 
8–10 nm. (Right) The filaments were decorated with 5 nm gold par-
ticles (arrows) by immunogold labeling using an anti-αS antibody, 
thus verifying that they were assembled from αS. Similar filamentous 
structures were not detected in apoptotic bodies from null M17D cells 
(data not shown). Scale bar: 100 nm. c Thioflavin T binding assay 
for sonicated apoptotic bodies derived from differentiated Myc-αS 
cells and mock-transfected cells with 36 h of puromycin treatment 
to induce apoptosis. Apoptotic bodies containing αS-positive fila-
ments shown in (b) were used as positive control. The PBS solution 
was used as blank. d Immunocytochemistry showed Myc immunore-
activity outside and inside αS-Flag cells treated with sonicated apop-
totic bodies from Myc-αS cells. Similar findings are not observed in 
control cells treated with sonicated apoptotic bodies from null M17D 
cells. Z-stack imaging confirmed the internalization of Myc-positive 
αS aggregates. e Neuronal cells can take up αS aggregates released 
from surrounding apoptotic cells. αS-Flag cells were co-cultured with 
Myc-αS or mock transfected M17D cells at equal density and sub-
jected to differentiation for 5 days and then maintained in media with 
or without puromycin for another 5 days. After that, cells were fixed 
for immunocytochemical staining with antibodies to Myc and Flag 
and counterstaining with DAPI. Arrows and arrowheads denote Myc-
positive aggregates from apoptotic bodies. Asterisk (*) and number 
sign (#), respectively, marked the apoptotic bodies from Myc-αS or 
mock transfected cells. Scale bar: 10 µm for all pictures
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αS aggregates from apoptotic bodies can be taken up by 
neuronal cells
Since αS aggregates in apoptotic bodies can be released 
upon disruption of the cell membrane, we investigated if 
aggregates of αS can be internalized by surrounding cells as 
described in previous study [11]. To address this issue, we 
employed two different neuronal cell models derived from 
M17D neuroblastoma cell line. One overexpresses Myc-
tagged αS (Myc-αS) is neomycin resistant and sensitive to 
puromycin; the other overexpresses Flag-tagged αS and is 
puromycin resistant, but sensitive to neomycin. Differen-
tiated Myc-αS cells were treated with puromycin, which 
triggers apoptosis, for 36 h to produce Myc-αS aggregates 
associated with apoptotic bodies [41]. Isolated apoptotic 
bodies were sonicated for a thioflavin T binding assay [30] 
to first confirm the formation of filamentous αS (Fig. 5c), 
then added to differentiated αS-Flag cells. Apoptotic bodies 
from puromycin-treated differentiated mock transfectants 
were used as a control. After 3 days of exposure to soni-
cated apoptotic bodies, cells were fixed and immunolabeled 
with antibodies to Flag and Myc tags. Myc-αS aggregates 
were observed on the cell surface and in the cytoplasm of 
most αS-Flag cells treated with Myc-αS sonicated apop-
totic bodies, but not in control cells (Fig. 5d). These find-
ings suggest that Myc-αS aggregates can bind to and be 
taken up by αS-Flag cells.
To determine if neuronal cells can directly take up αS 
aggregates released from surrounding apoptotic cells, 
αS-Flag cells were co-cultured with Myc-αS or mock 
transfected M17D cells at equal density and subjected to 
differentiation for 5 days and maintained in media with 
or without puromycin for another 5 days before fixation 
and immunostaining. Apoptotic bodies, characterized by 
DAPI-positive nuclear debris, were observed in puromycin-
sensitive Myc-αS cells bound to Flag-αS cells (Fig. 5e). 
In addition, apoptotic bodies in the process of decomposi-
tion appeared to be internalized into puromycin-resistant 
αS-Flag cells, suggesting that the apoptosis-induced αS 
aggregates can spread to surrounding cells in vitro. Further-
more, about 10 ± 3 % of the αS-Flag cells had internal-
ized Myc-immunopositive particles that were co-labeled 
with Flag antibody (Fig. 5e), consistent with recruitment of 
endogenous αS-Flag protein into Myc-αS seeds.
Apoptosis‑derived αS aggregates can be taken up by 
cells in vivo
To determine if apoptosis-induced αS aggregates can be 
taken up by neighboring cells in vivo, apoptotic bodies 
from STS-treated differentiated BE(2)-M17D/3D5 cells 
with and without αS overexpression were isolated and ster-
eotaxically injected into somatosensory cortex and dorsal 
neostriatum of wild-type C57BL/6 mice at ≈12 months of 
age following methods of Luk et al. [42]. Cell lysates from 
BE(2)-M17D/3D5 cells with αS overexpression, but with-
out STS treatment, were included as a control. All injected 
materials were subjected to thioflavin T assay and SDS-
PAGE/western blots (Fig. 6a, b) to confirm the presence 
of αS aggregates in the materials used for brain injection. 
After 1 week, brains were harvested, fixed and embed-
ded in paraffin for immunohistochemical studies. Human 
αS pathology was detected in the vicinity of the injected 
lysates from STS-treated cells in the form of neocortical 
neuronal perinuclear αS deposits (Fig. 6d, ii1 in  c), while 
thread-like and dot-like αS deposits were detected in soma-
tosensory cortex and dorsal neostriatum (Fig. 6c, insets). In 
contrast, cell lysates not treated with STS or those treated 
with STS, but not overexpressing αS, did not have neu-
ronal cytoplasmic or neuritic αS pathology (Fig. 6c, insets). 
These results suggest that αS aggregates from apoptotic 
neurons can be taken up by neurons in vivo.
Discussion
Our study suggests that neuronal αS aggregation may be 
triggered in some cases by proaggregant nuclear factor(s) 
associated with apoptosis. These initial aggregates may 
then serve as sources for αS pathology in the immedi-
ate vicinity of the affected neurons, which may eventually 
propagate to more distant sites, possibly by cell-to-cell 
transmission. Although we demonstrated that filamen-
tous αS aggregates form quickly in apoptotic neurons, it 
remains to be determined whether this process occurs in 
PD and related disorders.
Apoptosis is thought to play a role in neuronal cell 
death in PD and related disorders. Specifically, markers of 
apoptosis have been demonstrated in postmortem brains 
of PD [14, 15], as well as animal models [16, 17] and cel-
lular models of PD [18, 19]. Moreover, it has been sug-
gested that apoptosis is the most common type of neuronal 
death in PD and that there is a proapoptotic environment 
in the substantia nigra in PD [14]. Therefore, the proapop-
totic environment and apoptotic neuronal death in PD and 
related disorders provide support for a role of apoptosis-
associated proaggregant factor(s) in αS aggregation.
Effective clearance mechanisms in the brain quickly 
remove apoptotic neurons and their breakdown products 
[43]. Under normal circumstance αS aggregates would 
most likely be cleared and not propagate to adjacent cells. 
When neuronal death occurs in vulnerable neuronal popu-
lations in PD and related disorders, there may be incom-
plete clearance of breakdown products from apoptotic neu-
rons and subsequent propagation of αS aggregates. Aging 
is the major risk factor for PD, and it is associated with 
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decline in function of the immune system [44]. Thus, in 
the aged brain apoptosis-associated αS aggregates may be 
more prone to propagation.
A caveat of our studies is that they were conducted in a 
human dopaminergic cell line that inducibly overexpresses 
αS. This issue is raised because a critical concentration of 
αS is required to initiate its assembly [33, 45], and the neu-
ronal cultures used in many PD cell models have αS over-
expression. The rationale for using models with αS overex-
pression is that familial PD with multiplication of the αS 
gene (SNCA) have increased expression of wild-type αS 
[46–49] as well as  severe αS pathology [50]. Even in nor-
mal human aging and in older animal brains, αS expression 
levels have been shown to be increased compared to 
younger individuals [51–54]. Although it remains unclear 
what concentration of αS is critical for its aggregation in 
PD and related disorders, the fact that αS aggregates can 
be observed in brains of aged animals and neurologically 
normal humans indicates that on a cell-by-cell basis there is 
a sufficient concentration of αS to lead to aggregation even 
in normal individuals.
We propose that rapid formation of αS aggregates in 
neurons undergoing apoptosis is a consequence of nucleo-
cytoplasmic barrier disruption and the subsequent interac-
tion between cytoplasmic αS and proaggregant nuclear 
factor(s). Although previous studies have shown that αS 
Fig. 6  Apoptotic bodies derived αS aggregates can be taken up by 
neuronal cells in vivo upon inoculation into mouse brain. Apoptotic 
bodies from STS-treated BE(2)-M17D/3D5 cells with or without 
αS induction, respectively, referred to as STS+/αS+ and STS+/
αS−, were isolated and injected into brains of mice around age of 
12 months. Cell lysates from BE(2)-M17D/3D5 cells with αS induc-
tion but without STS treatment was also included as another control 
(STS-/αS+). All injected materials were subjected to a thioflavin 
T assay to confirm the formation of filamentous αS and with SDS-
PAGE/western blotting to confirm SDS-insolubility of αS aggregates. 
Apoptotic bodies containing αS-positive filaments shown in Fig. 5b 
were used as positive control for (a). Sections from the injected 
brain region were subjected to (c) immunohistochemical stain-
ing with LB509 to human αS and (d) immunofluorescence staining 
with LB509 and MAP2 to confirm that neuronal uptake of human αS 
aggregates can be only observed in mouse brain injected with apop-
totic bodies (STS+/αS+). Black arrows in (c) denote neuron-like 
cells with internalized αS aggregates. White arrows in (d) denote 
MAP2 and human αS aggregates positive neurons. Scale bar: 2 mm 
for i, ii and iii, 60 µm for i1, ii1 to ii3 and iii1 in (c), 10 µm for (d)
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can be transported into the nucleus upon induction of oxi-
dative stress either as an N-terminal truncated form [55] or 
as full length form mediated by importin [56], these mech-
anisms are probably not relevant to our observations. First, 
using fluorescent complementation assays that are depend-
ent upon integration of full-length tagged αS molecules to 
monitor αS oligomerization, we observed nuclear signals 
upon indication of apoptosis. Second, we did not detect 
evidence of truncated αS in western blots of nuclear frac-
tions. Thus, it does not appear that truncation of αS is nec-
essary for nuclear translocation in the setting of apoptosis. 
Third, our results showed that αS aggregation associated 
with apoptosis is accompanied by degradation of nuclear 
envelope (Figs. 1, 2). Although we cannot completely 
exclude the possibility that some αS may be transported 
into the nucleus by importin during apoptosis, this physi-
ological process of nuclear pore complex transport may be 
minimal in a cell where there is considerable disruption of 
the nuclear envelope.
The αS aggregates formed in apoptotic neurons share 
important features with pathological αS from PD and 
related disorders, such as filamentous structures, thioflavin 
binding, serine-129 phosphorylation and the ability to enter 
neuronal cells, suggesting similarities between αS aggre-
gates formed under in vitro and in vivo conditions.
Although we clearly demonstrated predominant nuclear 
localization of proaggregant factor(s) and cellular uptake 
of αS aggregates formed upon disruption of nuclear enve-
lope, we do not know the nature of nuclear proaggregant 
factor(s) and how αS rapidly forms aggregates upon inter-
action with these factors. Since it has been shown that the 
loss of nuclear integrity is accelerated in post-mitotic cells 
in an age-dependent manner [57], it is possible that chronic 
nuclear “leakiness” of proaggregant factor(s) might also 
contribute to accumulation of αS aggregates in brains of 
aged human [51].
Overall, our study suggests that a source of pathologi-
cal αS in PD and related disorders might be from apop-
totic neurons in which αS rapidly forms aggregates due 
to disruption of nuclear membrane and exposure of cyto-
solic αS to proaggregant nuclear factor(s). Accordingly, 
at least some αS aggregates might be a secondary phe-
nomenon generated during neuronal apoptosis. The pri-
mary insult that leads to apoptosis is unknown; however, 
once triggered, the effects of apoptosis on αS may accel-
erate a pathological cascade that eventually leads to local 
and more distant neurodegeneration. While it is important 
to determine the cause of neuronal apoptosis or leakiness 
of nuclear membrane that may possibly expose cytosolic 
αS to nuclear proaggregant factors in selectively vulner-
able neuronal populations in PD and related disorders, 
finding ways to limit the effects of apoptosis on αS aggre-
gation, deposition, local uptake and propagation might 
significantly impact progression of the disease. The current 
observations suggest novel processes in the pathogenesis of 
PD and related disorders and may open the door to innova-
tive treatments.
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